Compare CAVA Group Inc (CAVA) vs TG Therapeutics Inc (TGTX) Price & Performance

CAVA Group (CAVA) is trading at $69.47, up 12.81% following strong Q2 2026 earnings that beat estimates with $0.19 EPS and 31.3% revenue growth. The stock shows bearish technical signals despite recent momentum, with key resistance at $62-64. Fundamentally, CAVA maintains robust revenue expansion and profitability with 24.69% gross margins, though valuation multiples remain elevated at P/E of 108.59.

The outlook remains positive given analyst consensus of 19 buys and $89.75 price target, representing 29% upside potential. Key risks include high valuation sensitivity, competitive pressures in fast-casual dining, and execution challenges in restaurant expansion. Recent same-store sales growth of 9% supports continued momentum if operational excellence persists.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.